GlassScriptPhysician profile
Mamatha Gandhi
NPI 1154587897
$3,412.03
in general payments reported to CMS, 2019-2025
26 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2021: $687 · 2022: $1,048 · 2023: $1,003 · 2024: $402 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.34 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $661.69 | 2019-2024 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $365.33 | 2021-2023 | Krystexxa |
| Akebia Therapeutics INC | $353.11 | 2021-2024 | Auryxia, Vafseo |
| Vifor Pharma, INC. | $248.37 | 2021-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $244.25 | 2021-2024 | |
| Opko Pharmaceuticals, LLC | $241.37 | 2021-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $180.93 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Amgen INC. | $162.22 | 2019-2024 | Krystexxa |
| Calliditas Therapeutics US INC. | $139.96 | 2022-2023 | Tarpeyo |
| Travere Therapeutics, INC. | $135.11 | 2023-2024 | |
| Baxter Healthcare | $96.58 | 2022-2024 | Renal - Pd, Renal - Acute |
| Alexion Pharmaceuticals, INC. | $67.24 | 2022-2023 | Soliris |
| Vantive US Healthcare LLC | $64.43 | 2025 | Renal - Pd |
| Novo Nordisk INC | $59.71 | 2023-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $55.18 | 2022-2023 | Benlysta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.94 | 2023-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $47.79 | 2019-2022 | |
| Daiichi Sankyo INC. | $47.29 | 2022 | |
| Scpharmaceuticals INC. | $33.00 | 2024 | |
| La Jolla Pharmaceutical Company | $31.78 | 2022 | |
| Shield Therapeutics INC | $29.19 | 2023-2024 | Accrufer |
| Novartis Pharmaceuticals Corporation | $25.32 | 2024 | |
| Abbvie INC. | $21.83 | 2025 | |
| Mallinckrodt Hospital Products INC. | $19.41 | 2021 | |
| Corcept Therapeutics | $17.83 | 2021 | |
| Biomerieux INC | $13.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamatha Gandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.